Overview
- The companies announced binding settlement terms on Monday that resolve all patent and related disputes worldwide over Ascendis’s drug Yuviwel.
- Ascendis agreed to pay BioMarin 20% of net U.S. sales and 18% of net sales in the EU, Brazil and South Korea, with payments retroactive to Yuviwel’s first commercial sale and running until May 2030.
- BioMarin granted Ascendis a license to patents tied to C‑type natriuretic peptide technology for all current and potential Yuviwel uses, including achondroplasia, hypochondroplasia and combination therapies.
- As part of the agreement BioMarin will dismiss its Section 337 complaint at the U.S. International Trade Commission and the parties will drop or resolve litigation in Brazil, Denmark, Germany, South Korea and the U.S. Northern District of California; Ascendis also agreed not to challenge BioMarin’s patents and accepted mutual regulatory non‑interference.
- The settlement validates BioMarin’s CNP platform and creates a predictable, near‑term royalty line that analysts say will feed into BioMarin’s financials while allowing continued patient access to Yuviwel globally.